Pimavanserin Tartrate
1 NDC across 1 manufacturer|0 Generic,1 Brand
Pimavanserin Tartrate is used to treat hallucinations and parkinson disease, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Apr 29, 2016, and the first generic was approved Jan 16, 2024. In 2024, Medicare Part D spent $658 million on Pimavanserin Tartrate across 143,000 claims for 17,000 beneficiaries.
Pimavanserin Tartrate is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $170.50 to $170.50 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$170.50 – $170.50
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Acadia Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Atypical Antipsychotic class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing PIMAVANSERIN TARTRATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
NUPLAZID 34 MG CAPSULE | $170.4960 per EA | — |
Frequently Asked Questions
What is Pimavanserin Tartrate used to treat?
Pimavanserin Tartrate is used to treat hallucinations and parkinson disease, per the National Library of Medicine's MED-RT classification.
When did Pimavanserin Tartrate become available as a generic?
FDA approved the first generic Pimavanserin Tartrate (ANDA) on Jan 16, 2024.
How much does Medicare spend on Pimavanserin Tartrate?
In 2024, Medicare Part D spent $658 million on Pimavanserin Tartrate across 143,000 claims for 17,000 beneficiaries.
How many Pimavanserin Tartrate products are on the market?
The Pimavanserin Tartrate drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Pimavanserin Tartrate?
NADAC reference prices for Pimavanserin Tartrate range from $170.4960 to $170.4960 per EA.
Which manufacturers make Pimavanserin Tartrate?
1 manufacturer lists Pimavanserin Tartrate in NADAC. Ranked by number of NDCs, the largest are Acadia Pharmaceuticals Inc. (1).